Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

COPENHAGEN, Denmark I June 26, 2025 I Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of the first of two clinical trials designed to support ...

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population.

Ireland has reported the first case anywhere of mpox in a fully vaccinated person, despite having a high immune response at ...

Danish vaccine specialist Bavarian Nordic (OMX: BAVA) is set to collect $160 million from the sale of a US priority review ...

Tech transfer of MVA-BN® will help increase global mpox vaccine manufacturing capacity and further expand the equitable access to vulnerable populations.Serum Institute of India obtains license to MVA ...

Bavarian Nordic’s Q4 2024 earnings call with investors bordered on celebratory as the vaccine maker ended a successful year, in part on the back of its mpox vaccine. The company has worked with ...

Denmark-based Bavarian Nordic has sold a priority review voucher (PRV) for $160m, a day after the US Food and Drug Administration (FDA) announced a new scheme utilising the fast-track tickets.

COPENHAGEN, Denmark, November 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons ...